Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
After a long day of presentations and deliberations, the FDAs Cellular, Tissue, and Gene Therapies Advisory Committee voted overwhelmingly to reject BrainStorm Cell Therapeutics experimental amyotrophic lateral sclerosis (ALS) therapy NurOwn
10.3410/B5-1 649 UverskyV
In the Y-maze test, the control group presented significantly fewer altered triplets than the WT group did ( P = 0.0001
For the parallel review of TB-500 specifically, see our TB-500 FDA approval status 2026 breakdown
Second, the sustained cognitive improvements that persist months after treatment cessation suggest structural brain changes, not merely temporary pharmacological effects
US$ 27.84
US$ 21.84
US$ 20.69
